• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002566.SZ
Share

Jilin Jian Yisheng Pharmaceutical Co., Ltd. Stocks

CN¥ 7.14Last Updated 22.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 343.95M

CN¥ 7.14
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jilin Jian Yisheng Pharmaceutical Co., Ltd. is an enterprise based in Ji'an, China, established in 1997. The company specializes in the production and distribution of a diverse array of goods across the Chinese market. Its offerings include various pharmaceutical products, traditional Chinese herbal medicines, cosmetic items, and food products. Within its medical and health divisions, the firm provides goods in formats such as capsules, injections, tablets, and granules, with a particular emphasis on specialized medicinal products derived from Ginseng, as well as a selection of bee-related products.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 21:39

Viking Therapeutics soars 31% intraday on upbeat data for its obesity shot

22.09.2026 20:59

Redburn Expects a Stock Market Crash for Non-Cloud Providers. What's Wrong with the AI Computing Market?

22.09.2026 20:23

Bank of America forecasts that Brent crude oil prices will rise above $150 in 2027

22.09.2026 20:10

The manufacturer of Ozempic is considering entering the hair loss treatment market

22.09.2026 19:13

Rising inflation has become the main risk for wealthy investors. Where do they keep their money?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026